Malenka Robert C. 4

What Happened Robert C. Malenka, a director of MapLight Therapeutics (MPLT), sold a total of 7,040 shares in open-market transactions: 7,039 shares on 2026-02-02 at a weighted average price of $18.02 for $126,843, and 1 share on 2026-02-03 at $18.00 for $18. The filing indicates these sales were made to cover tax obligations related to the settlement of restricted stock units (RSUs), a routine tax-withholding sale rather than a directional bet on the company.

Key Details

• Transaction dates and prices: 2026-02-02 — 7,039 shares at a weighted average $18.02 (sales ranged $18.00–$18.14); 2026-02-03 — 1 share at $18.00. Total proceeds ≈ $126,861.
• Shares owned after the transaction: not specified in the Form 4; filing notes the shares are held by the Robert C. Malenka Living Trust (the reporting person is sole trustee with voting/dispositive power).
• Footnotes: F1 — sales to cover tax withholding on RSU settlement; F2 — reported price is a weighted average, multiple sale prices within $18.00–$18.14; F3 — shares held in Malenka living trust.
• Timeliness: Report filed 2026-02-04 for transactions occurring 2026-02-02 and 2026-02-03 (filed within the standard Form 4 reporting window).

Context These sales were tied to RSU tax withholding (common when restricted units vest) and are typically considered routine administrative transactions rather than a strong signal about insider sentiment. The filing also notes retained securities remain subject to a 180‑day IPO lock-up tied to the company’s October 26, 2025 prospectus.